Mintz advised Hopewell Therapeutics in the transaction. Hopewell Therapeutics, a biotechnology company with a differentiated lipid nanoparticle platform harnessing unique ionizable lipid chemistry, in its Seed...
You must be a Standard 1 Year member to access this content.
Mintz represented CXL Ophthalmics (CXLO) on the deal while Foley & Lardner LLP represented AXA IM Alts. CXL Ophthalmics (CXLO), a clinical-stage company developing a minimally-invasive...
You must be a Standard 1 Year member to access this content.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advised Granahan, while Seward & Kissel advised Kudu on the deal. Granahan Investment Management, Inc. (GIM), a small...
You must be a Standard 1 Year member to access this content.
Mintz advised Cardurion Pharmaceuticals on the deal. Cardurion Pharmaceuticals, Inc. (Cardurion), a clinical-stage biotechnology company, announced a private investment of up to $300 million from Bain Capital...
You must be a Standard 1 Year member to access this content.
Mintz advised Vicarious Surgical Inc. on the deal. Vicarious Surgical Inc., a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures...
You must be a Standard 1 Year member to access this content.
